New government legislation is needed to ensure full transparency of payments made by pharmaceutical companies to UK healthcare professionals and organisations to protect patient safety and public ...

The five-year voluntary pricing deal between pharma companies and the U.K. Department of Health is under severe pressure after the rebate the industry is due to pay leapt from 15.3% in 2024 to 22.9% ...